C3 GLOMERULOPATHY (C3G)
Clinical trials for C3 GLOMERULOPATHY (C3G) explained in plain language.
Never miss a new study
Get alerted when new C3 GLOMERULOPATHY (C3G) trials appear
Sign up with your email to follow new studies for C3 GLOMERULOPATHY (C3G), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a targeted therapy tame rare kidney diseases in daily practice?
Disease control Recruiting nowThis study looks at how well the medication pegcetacoplan works and how safe it is for people with two rare kidney conditions: C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). Researchers will follow about 150 patients who are…
Matched conditions: C3 GLOMERULOPATHY (C3G)
Phase: PHASE4 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for rare kidney disease? first human trial of CPV-104 begins
Disease control Recruiting nowThis study tests CPV-104, a new medicine designed to calm an overactive immune system part that attacks the kidneys in C3 glomerulopathy (C3G), a rare kidney disorder. It is the first time CPV-104 is given to people. The trial includes 39 participants: healthy volunteers receivin…
Matched conditions: C3 GLOMERULOPATHY (C3G)
Phase: PHASE1 • Sponsor: eleva GmbH • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New hope for rare blood and kidney diseases: iptacopan access program opens
Disease control AVAILABLEThis program provides early access to the drug iptacopan for people with serious or life-threatening C3 glomerulopathy (C3G) or paroxysmal nocturnal hemoglobinuria (PNH) who have no other treatment options. It is designed for patients who cannot join a clinical trial or have exha…
Matched conditions: C3 GLOMERULOPATHY (C3G)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC